Is Octreotide Benefitial in Patients with Metastatic Gastroenteropancreatic (GEP) and Hepatobiliary Neuroendocrine Carcinoma (NEC)? Abstract #608

Introduction: Neuroendocrine carcinomas (NECs) of the gastroenteropancreatic (GEP) and hepatobiliary (HB) tract are rare and a heterogenous group of malignancies. Octreotide showed the anti-tumor activity in well-differentiated metastatic midgut neuroendocrine tumors (NETs).
Aim(s): It has not been evaluated whether octreotide in NEC affects survival outcome or not.
Materials and methods: We analyzed 17 patients (6 ; HB- and 11 ; GEP- tract) with metastatic NEC who had been diagnosed between January 2009 and June 2012. All patients had one or more cytotoxic chemotherapy and nin had received octreotide as a single agent (n=3) or combination of cytotoxic chemotherapy (n=6) during treatment period.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Seung Kim
Authors: Kim S
Keywords: NEC, octreotide, GEP, HB

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1091 IFNα versus IFNα Plus Octreotide LAR in Treatment of NETs
Introduction: It is still unknown whether the combination of IFNα with octreotide LAR has benefit compared with IFNα alone
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Galina Emelianova
#2071 ElevatION:NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment
Introduction: Monoclonal antibody (mAb) inhibitors of immune checkpoints, including anti–PD-1 and anti–PD-L1, have become established treatment options in various solid tumors. However, there is a paucity of data on treatment effect of checkpoint inhibition in neuroendocrine tumors (NET) and neuroendocrine carcinoma (NEC). PDR001 is a high-affinity, humanized IgG4 mAb directed against PD-1 that blocks the binding of PD-L1 and PD-L2 to PD-1.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Anamika Gulati
Authors: Yao J C, Fazio N, Li D, Pavel M, ...
Keywords: PDR001, immunotherapy, NET
#350 RAD001 and Octreotide LAR as first-line treatment of well differentiated neuroendocrine tumors: an I.T.M.O. (Italian Trials in Medical Oncology) group study
Introduction: RAD001 has shown antitumor activity in pancreatic neuroendocrine tumors (NETs) and it seems to work synergistically with somatostatine analogues.
Conference:
Category: Basic
Presenting Author: Dr Laura Catena
#617 Incidence and Geographic Distribution of Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs): A Systematic Review of the Literature
Introduction: Based on the literature, the world-wide incidence of neuroendocrine tumors (NETs) seems to be increasing, however, a systematic literature overview is lacking.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Antongiulio Faggiano
#1297 Efficacy and Safety of Targeted Agents for Treatment of Gastroenteropancreatic (GEP) Neuroendocrine Tumor (NET): Single Center Experience
Introduction: As clinical features of NET are heterogeneous, the evaluation of real-world outcomes with everolimus and sunitinib are necessary.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: MD Changhoon Yoo
Authors: Yoo C, Cho H, Kim K, Chang H M, ...